A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Bleomycin (Primary) ; Brentuximab vedotin (Primary) ; Dacarbazine (Primary) ; Nivolumab (Primary) ; Vinblastine (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 05 Dec 2018 Planned End Date changed from 23 Oct 2020 to 1 Nov 2020.
- 05 Dec 2018 Planned primary completion date changed from 23 Oct 2020 to 1 Nov 2020.
- 25 Oct 2018 New trial record